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Background: Patients with diabetes are at increased risk of severe influenza disease; influenza vaccination for these
patients is therefore recommended by the World Health Organization and several National Immunization Technical
Advisory Groups. However, no systematic review has evaluated the effects of influenza vaccines for patients with
diabetes.
Methods: We conducted a systematic review and meta-analysis by searching Medline, Embase, Cochrane Central
Register of Controlled Trials, and ClinicalTrials.gov from inception until November 2014. We included all types of
studies reporting on the efficacy, effectiveness, and/or safety of influenza vaccination in patients with type 1 and
type 2 diabetes of all ages. We used the Newcastle-Ottawa scale to assess risk of bias in observational studies.
Residual confounding was addressed by comparing estimates of vaccine effectiveness (VE) during influenza seasons
to those obtained during off-seasons. Quality of the evidence for each outcome was assessed using the GRADE
methodology.
Results: Following review of 1,444 articles, 11 observational studies with a total of 170,924 participants were
included. In diabetic patients of working-age (18–64 years), influenza vaccination prevented all-cause hospitalization
with a pooled VE of 58% (95% CI, 6–81%) and hospitalization due to influenza or pneumonia (VE 43%; 95% CI,
28–54%), whereas no effects on all-cause mortality and influenza-like illness (ILI) were observed. In the elderly (65+),
influenza vaccination prevented all-cause mortality (VE 38%; 95% CI, 32–43%), all-cause hospitalization (VE 23%;
95% CI, 1–40%), hospitalization due to influenza or pneumonia (VE 45%; 95% CI, 34–53%), and ILI (VE 13%; 95% CI,
10–16%). However, significant off-season estimates for several outcomes indicated residual confounding, particularly
in elderly patients. Quality of the evidence was low to very low for all outcomes. Laboratory-confirmed influenza
infections were not reported.
Conclusions: Due to strong residual confounding in most of the identified studies, the available evidence is
insufficient to determine the magnitude of benefit that diabetic people derive from seasonal influenza vaccination.
Adequately powered randomized controlled trials or quasi-experimental studies using laboratory-confirmed
influenza-specific outcomes are urgently needed.
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Worldwide, more than 347 million people live with diabetes
[1]. Since patients with diabetes are at increased risk of
medical complications attributable to influenza infections
[2], annual vaccination against influenza is recommended
for these patients by the World Health Organization
(WHO) [3] and several National Immunization Technical
Advisory Groups (NITAGs) [4-7]. However, the underlying
pathology of greater susceptibility to influenza and its com-
plications is not well understood. An impaired immune re-
sponse has been hypothesized to be responsible for an
increased risk of infection [8-10] as well as infection-related
complications in patients with diabetes [11,12]. If this hy-
pothesis holds true, the immune response to influenza vac-
cines might be impaired in diabetic patients as well. In fact,
while some studies found a reduced immune response to
vaccination in patients with diabetes [13,14], others did not
detect a difference in the humoral response between dia-
betic patients and healthy controls [15-18]. However, the
value of these studies is limited not only because of their
small size and contradicting findings, but also because in-
fluenza antibody titers do not perfectly correlate with clin-
ical protection [19]. Therefore, evidence from post-
marketing studies with clinical outcomes is highly desirable.
Knowledge of the benefits and harms is important to
inform decision-making for vaccination and crucial for
public health authorities when defining vaccination tar-
get groups. As such, we performed a systematic review
and meta-analysis on influenza vaccine efficacy/effective-
ness (VE) and safety in diabetic patients of all ages. We
draw particular attention on the analysis of bias and
confounding and used the methodology developed by
the Grading of Recommendations Assessment and
Evaluation (GRADE) working group to assess the quality
of evidence for each outcome.
Methods
Eligibility criteria
To be eligible for this systematic review, a study had to be
an original report on the efficacy, effectiveness, and/or
safety of vaccines against seasonal influenza in individuals
with diabetes mellitus. Patients with type 1 and type 2 dia-
betes of all ages were included. The control group had to
be either unvaccinated or must have received placebo. All
reported clinical or laboratory-confirmed outcomes and
all types of local and systemic adverse events were consid-
ered. No restrictions were made regarding study type,
publication language, and publication status.
Search strategy and data extraction
The systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement [20]. The study proto-
col of this review is available in Additional file 1. Theliterature search was independently developed by two re-
viewers (CR and TH) and discussed with a librarian of the
Robert Koch Institute. Two reviewers (CR and TH) inde-
pendently searched MEDLINE, EMBASE, and Cochrane
Central Register of Controlled Trials (date of last search:
November 25, 2014) and the screening process was not
different for citations versus full-text articles. For complete
search strategy, see Additional file 2. In addition, Clinical-
Trials.gov and reference lists of all identified studies were
reviewed for additional studies.
From each eligible original study, two independent re-
viewers (CR and TH) extracted study characteristics and
assessed methodological quality, using standardized
forms. Extraction forms were pilot tested with the first
identified study and disease-specific data (e.g., diagnosis
of type of diabetes; type of therapy) were added. For one
study [21], the corresponding author was contacted to
resolve discrepancies in published data. For a study,
which was published as a congress abstract [22], we con-
tacted the authors to obtain further details. In case of
disagreements regarding screening, data extraction, and
quality assessment a final decision was made by consen-
sus or resolved by a third reviewer (OW). The following
information was extracted: country, year, study design,
age at vaccination, sex, identification of diabetic patients,
conflict of interest declared by study authors, vaccine
used (name, manufacturer), number of vaccinated and
unvaccinated participants, proportion of participants lost
to follow up, relative risks, odds ratios, hazard ratios, risk
difference for defined outcomes, confounder-adjusted esti-
mates, confounders considered, and control period (off-
season) estimates.
Assessment of bias
The Cochrane Risk of Bias tool was used to assess risk
of bias in randomized controlled trials (RCTs) and the
Newcastle-Ottawa Scale was used to assess the risk of
bias in quasi-experimental studies and in observational
studies. Following the suggestions made by the Cochrane
Collaboration [23], we assessed risk of bias separately for
each outcome and expressed the results as a considered
judgment, using the categories ‘high risk of bias’, ‘low
risk of bias’, and ‘unclear risk of bias’. In addition, we
assessed the risk of healthy vaccinee bias and confound-
ing by indication in the included studies. Details of the
methodology are described in Additional file 3.
Assessment of quality of the body of evidence
We used the GRADE methodology to assess the quality of
the respective body of evidence for each outcome [24,25].
According to GRADE, outcomes of an intervention
are categorized into four levels of evidence quality: +very
low, ++ low, +++ moderate, and ++++ high. In GRADE,
bodies of evidence from RCTs start as high quality
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as low quality evidence. Defined criteria are applied to ei-
ther decrease or increase quality of evidence rating. De-
tails on the GRADE methodology can be found elsewhere
[25-27]. Applying the principle of assessing the best avail-
able evidence, we assessed the results of the confounder-
adjusted analyses with GRADE.
Statistical analysis
Abstracted data were aggregated in tables, together with
risk of bias assessments. Risk ratios, odds ratios, risk dif-
ferences and corresponding 95% confidence intervals
(95% CIs) were either calculated or extracted directly
from the publications. VE was calculated as 1–(risk ratio
comparing vaccine and control recipients) × 100.
All analyses were performed separately according to
study design and age group. Where data from more than
one study on a given outcome were available, we per-
formed meta-analysis, using a random-effects model to
account for heterogeneity. I2 was used to quantify the
extent of heterogeneity. In addition to pooling crude es-
timates, we pooled confounder-adjusted estimates if they
were adjusted at least for age, sex, and comorbidities. To
evaluate the presence of residual confounding, we con-
trasted estimates of VE measured during the influenza
season to estimates measured during ‘control periods’
outside the influenza season in the same studies. Using
the confounder-adjusted estimate, residual confounding
was defined to be present if vaccination had a statisti-
cally significant effect on a given outcome in the absence
of influenza virus circulation (‘off-season’). Formal test-
ing for publication bias was not done since study num-
bers for each outcome were too small. Calculations were
done using STATA 12 (StataCorp LP, Texas, USA) and
Review Manager (RevMan 5.2, Cochrane Collaboration).
The results of the GRADE evidence rating were re-




After removal of duplicates, we identified 1,444 records
in electronic databases (Figure 1) and finally included a
total of 11 original studies comprising data of 170,924
diabetic patients. Of these, 10 were identified via data-
bases and one study [29] was identified from a reference
list. In addition, we identified one conference abstract
[22] which, however, did not provided sufficient data to
be extracted. We did not identify further unpublished
data. All studies were published in English. The main
reasons for exclusion were that no data on vaccine ef-
fectiveness or vaccine safety in diabetic patients were
reported, that studies did not provide original data (e.g.,
narrative review or guidelines), or that only vaccinecoverage data on diabetic patients were provided (details
on excluded studies are reported in Additional file 4).
No additional studies reporting on influenza VE or safety
specifically in subgroups of diabetic patients were identi-
fied in the Cochrane review on influenza vaccination in
the elderly [30].
Study characteristics
We included six cohort [21,29,31-34] and five case–con-
trol [35-39] studies. No RCTs or other experimental or
quasi-experimental studies were identified. Six studies
[21,29,32,34,37,39] included patients aged 65 or older
and two case–control studies [35,38] provided stratified
analyses on both elderly and adults of working-age (18
to 64 years). None of the studies presented data on chil-
dren or adolescents. One article [31] did not report the
age of included patients (Table 1).
Nine of 11 studies used either International Classifica-
tion of Diseases Codes (ICD-9/10) or International Clas-
sification of Primary Care Codes from clinical records or
administrative databases to identify diabetic patients and
subsequent influenza disease. Only one study provided
data on the type of diabetes, glycemic control, and num-
ber of years that patients lived with diabetes [36]. One
study reported on three different vaccine types that were
used by included patients [37]. However, a stratified ana-
lysis (e.g., VE of adjuvanted vs. non-adjuvanted vaccines)
was not possible, since diabetic patients were not strati-
fied accordingly.
Five studies gave information on potential conflicts of
interest [32,35,37-39]. Of those, in one study, a co-
author received consulting fees and had served on an
advisory board of a pharmaceutical company [38].
Reported outcomes
Overall, six different clinical outcomes were reported.
Outcomes that were addressed by at least one of the stud-
ies were all-cause mortality, all-cause hospitalization,
hospitalization due to influenza or pneumonia (based on
hospital discharge diagnosis codes), influenza-like illness
(ILI), admission to an intensive care unit (ICU), and re-
spiratory failure (Additional file 5). Since it was unclear
whether the outcomes ICU-admissions and respiratory
failures reported in one study [39] were a subgroup ana-
lysis of hospitalized cases, these outcomes were excluded
from the final analysis. Two studies additionally provided
data on the compound outcome ‘hospitalization or death’
[29,38]. None of the studies reported data on vaccine
safety and none of the studies gave data on laboratory-
confirmed influenza infections. Four of 11 studies did not
report adjusted VE estimates [21,31,33,37] and one study
did not provide crude point estimates [35]. Three studies
measured ‘pseudo-effectiveness’ of influenza-related out-
comes off-season [21,32,35].
Figure 1 Flow chart for the systematic literature search and study selection related to efficacy, effectiveness, and safety of influenza
vaccines in diabetic patients.
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Outcome-specific risk of bias assessment is presented in
Additional file 6. In six cohort studies, eight estimates
were reported. In two cohort studies, risk of bias was
low regarding all-cause mortality and the compound
outcome hospitalization or death, respectively. The
remaining estimates, which were reported in cohort
studies, had a high risk of bias.
In the five case–control studies, 18 estimates for dif-
ferent outcomes were reported. Six estimates presented
by four studies indicated high risk of bias, whereas the
remaining 12 estimates were at low risk (Additional file
6). Notably, in one study [35] risk of bias differed within
the study among different outcomes and age groups: in
adults of working-age, risk of bias was high for all-cause
hospitalization but low for hospitalization due to influ-
enza or pneumonia and for ILI, whereas, among the eld-
erly, risk of bias was high for all these outcomes.
In 7 of the 11 included studies confounding by indica-
tion was likely (Additional file 3): baseline characteristics
showed that vaccinated participants had more comor-
bidities than unvaccinated participants. Healthy vaccineebias, however, was likely to be present in a subgroup of
patients in one study only; Lau et al. [35] showed that,
among the elderly, vaccinated patients had fewer comor-
bidities than unvaccinated participants.
Vaccine effectiveness in adults aged 18 to 64 years
Overall, three case–control and one cohort study pre-
sented data on working-age adults. Crude and adjusted
odds ratios for single studies for all outcomes are shown
in Additional file 5. In the pooled analysis (Table 2), ad-
justed point estimates correspond to VE of 58% (95% CI,
6–81%, I2 = 77%, n = 3) against all-cause hospitalization.
Point estimates regarding hospitalization due to influ-
enza or pneumonia were reported by only one study and
corresponded to a VE of 43% (95% CI, 28–54%, n = 1).
Regarding all-cause mortality and ILI, no statistically sig-
nificant protective effects were observed; however, ad-
justed estimates for each of the latter three outcomes
were reported by only one study. Off-season VE esti-
mates against all-cause hospitalization calculated in one
study were lower than estimates during influenza sea-
sons, but still showed a protective effect (VE, 27% (95%
Table 1 Characteristics of included studies on influenza vaccine effectiveness in diabetic patients
Author Study design, year Country Age in years
(mean or range)







Hak [29] Prospective, 1996/1997
and 1997/1998




ICD-9 codes, database of
managed care organizations
A(H3N2) in both seasons 14,915 in 96/97
21,991 in 97/98
Heymann [21] Retrospective, 2000/2001 Israel Vacc., 72.8 ± 0.6 Vacc., 51.8 ICD-9 codes, diabetes register
of healthcare service
Not reported 16,383
Non-vacc., 73.1 ± 0.5 Non-vacc., 42.1
Isotani [31] Retrospective, 1999/2000 Japan Not reported Not reported Outpatient clinic, unclear Influenza A 450
Rodriguez-Blanco [32] Retrospective, 2002–2005 Spain Vacc., 75.2 ± 6.5 Vacc., 39.8 ICD-9 codes, clinical records A(H3N2) 2,650
Non-vacc., 73.1 ± 6.9 Non-vacc., 42.2
Selvais [33] Prospective, 1995/96 Belgium 56.3 ± 15.9 years 55 Diabetes clinic, unclear Not reported 432
Schade [34] Retrospective, 1995–1997 US 65 to 114 years Not reported ICD-9 codes, hospital discharge Not reported 26,443 in 96/97
23,839 in 97/98
Case–control studies
Colquhoun [36] not matched, 1989 and 1993 UK ≤19–85 years Cases, n = 59 ICD-9 codes, diabetes register 1989, A(H3N2) 114 (37 cases,
77 controls)
Controls, n = 55 1993, A(H3N2) and B




ICD-9 codes, hospital discharge A(H1N1)pdm, and B 78 (46 cases,
32 controls)






Looijmans [38] Nested, 1999/2000 Netherlands Cases, 68.1 ± 13.7 Cases, 51.6 controls, 38.3 ICPC codes, general practitioners A(H3N2) 1,753 (192 cases,
1,561 controls)
Controls, 69.8 ± 12.6
Wang [39] Nested, 2001–2009 Taiwan Vacc., 73.1 ± 5.9 Vacc, 50.0 ICD-9 codes, NHRI-database Not reported 9,025 (4,571 vacc.,
4,454 non-vacc.)
Non-vacc., 73.2 ± 6.8 Non-vacc., 49.5
Total population 170,9243
1Median; 2Published as cohort study, however, due to matching of controls, this study was considered as case–control study here; 3Since overlapping of the study population reported by Hak et al. and Schade et al.
for two influenza seasons cannot be ruled out for calculation of the total population for each study numbers of only one season were used.














Table 2 Pooled crude and adjusted odd ratios of influenza vaccine effectiveness (per outcome) during influenza-season and off-season in vaccinated vs.
unvaccinated diabetic patients













0–17 No studies 0 – – 0 – – 0 – –
18–64 All-cause mortality
Case–control studies 1 0.46 (0.11–1.89) NA1 1 0.76 (0.07–8.06) NA1 0 – NA1
All-cause hospitalization
Case–control studies 2 0.32 (0.19–0.54) 0% 3 0.42 (0.19–0.94) 77% 1 0.73 (0.65–0.83) NA1
Influenza/pneumonia hospitalization
Case–control studies 0 – – 1 0.57 (0.46–0.72) NA1 1 0.88 (0.68–1.14) NA1
Influenza-like illness
Cohort studies 1 0.76 (0.50–1.15) NA1 0 – – 0 – –
Case–control studies 0 – – 1 0.99 (0.97–1.01) NA1 1 1.00 (0.90–1.12) NA1
≥65 All-cause mortality
Cohort studies 3 0.54 (0.37–0.79) 90% 2 0.62 (0.57–0.68) 0% 1 0.70 (0.37–1.31) NA1
Case–control studies 2 0.39 (0.35–0.43) 0% 2 0.44 (0.36–0.53) 0% 0 – –
All-cause hospitalization
Cohort studies 1 0.83 (0.72–0.95) NA1 0 – – 1 0.91 (0.71–1.17) NA1
Case–control studies 2 0.89 (0.81–0.98) 0% 3 0.77 (0.60–0.99) 94% 1 0.66 (0.59–0.74) NA1
Influenza/pneumonia hospitalization
Case–control studies 1 0.20 (0.07–0.61) NA1 1 0.55 (0.47–0.66) NA1 1 0.48 (0.32–0.70) NA1
Influenza-like illness
Case–control studies 0 – – 1 0.87 (0.84–0.90) NA1 1 0.82 (0.70–0.96) NA1
Not reported Influenza/pneumonia hospitalization
Cohort studies 1 1.75 (0.10–32.68) NA1 0 – – 0 – –
Influenza-like illness
Cohort studies 1 0.34 (0.02–5.85) NA1 0 – – 0 – –
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founding. Off-season VE estimates regarding other out-
comes were not statistically significant.
Vaccine effectiveness in elderly aged 65 and older
Crude and adjusted odds ratios for all outcomes in elderly
diabetic patients are shown in Table 2. In cohort studies,
pooled analysis of adjusted point estimates showed pro-
tective effects of influenza vaccination against all-cause
mortality (adjusted VE 38%, 95% CI, 32–43%, I2 = 0%,
n = 2). For the remaining outcomes, only crude point esti-
mates were reported by cohort studies and off-season esti-
mates did not indicate residual confounding here.
Pooled analysis of case–control studies indicated that
influenza vaccination prevented all-cause mortality (ad-
justed VE 56%, 95% CI, 47–64%, I2 = 0%, n = 2) and all-
cause hospitalization (adjusted VE 23%, 95% CI, 1–40%,
I2 = 94%, n = 3). Only one study [35] reported data on
VE against hospitalization due to influenza or pneumonia
(adjusted VE 45%, 95% CI, 34–53%, n = 1), and against ILI
(adjusted VE, 13%, 95% CI, 10–16%, n = 1). However,
significant VE estimates for all-cause hospitalization,
hospitalization due to influenza or pneumonia and for ILI
were identified also off-season, often even with higher
point estimates than during influenza seasons.
High statistical heterogeneity was observed regarding
the outcome all-cause hospitalization among both adults
at working age and the elderly. However, we did not find
appropriate explanations for these high values, possibly
due to the small number of studies.
Quality of evidence
For working-age adults (18 to 64 years), evidence for a
protective effect of influenza vaccination on all-cause
mortality was assessed as being of very low quality due
to a high imprecision of the estimate. The same quality
assessment applied to all-cause hospitalization, with esti-
mates having a high risk of bias and being imprecise.
Evidence for effects of influenza vaccination on
hospitalization due to influenza or pneumonia and effects
on ILI was assessed as being of low quality (Additional
file 7 for the GRADE evidence profile).
For elderly patients (65 years and older), evidence on
effectiveness for preventing all-cause hospitalization,
hospitalization due to pneumonia or influenza, and ILI
by influenza vaccination was rated as being of very low
quality due to serious risk of bias. For all-cause mortal-
ity, quality of evidence was low (Additional file 8 for the
GRADE evidence profile).
Discussion
The evidence on the effectiveness of influenza vaccin-
ation in preventing clinical outcomes in patients with
diabetes is limited for elderly and adults, and absent forchildren and adolescents. For elderly patients, the quality
of evidence was low for preventing all-cause mortality
and very low for all other clinical outcomes. In working-
age adults, vaccination was shown effective only against
hospitalization due to influenza or pneumonia (quality
of evidence: low), whereas no effect was found against
any other clinical outcome (quality of evidence: low to
very low). In the absence of RCTs, quality of evidence
was strongly limited through risk of bias and residual
confounding in the observational studies.
Why the evidence was limited
In our review, we found the currently available evidence
on the effectiveness of influenza vaccination in prevent-
ing clinical outcomes in diabetic patients to be limited
for several reasons. The first important limitation con-
cerns the unavailable data for specific age groups or out-
comes. Although a shift towards younger ages has been
observed in the manifestation of diabetes in several in-
dustrialized countries [40-43], no studies were identified
which reported data on influenza VE in diabetic children
or adolescents. Additionally, the number of studies on
working-age adults and elderly people with diabetes can
be regarded as relatively small given the public health
relevance of both diabetes and influenza. This ultimately
led to wide confidence intervals – at least for some out-
comes – which limited the conclusions that could be
drawn from these estimates. The lack of studies on
safety outcomes related to influenza vaccines when used
in diabetic patients was surprising. However, influenza
vaccines have been used for decades and safety did not
appear to be a serious issue in healthy adults or elderly
[30,44]. Regarding diabetic patients, one study compared
reactogenicity of trivalent inactivated influenza vaccines
with virosomal influenza vaccines in children with dia-
betes type 1 and found only transient and non-severe
adverse events in both groups [45]. Serious adverse
events in diabetic patients following influenza vaccin-
ation have been reported only in case studies. One study
reported two cases of pancreas transplant rejection in
patients with diabetes type 1 after immunization against
pandemic influenza (H1N1pdm) [46]. Another patient
with a family history of type 2 diabetes developed ful-
minant type 1 diabetes with thrombocytopenia within
7 days after seasonal influenza vaccination [47]. Thus,
overall, reactogenicity or severe side effects in patients
with diabetes does not seem to be frequent or different
from healthy adults.
A second limitation was the choice of case definitions.
In the observational studies included in our review, pa-
tients with diabetes were mainly identified via disease
classification codes. Due to the nature of register-based
studies, unspecific outcomes (i.e., outcomes without la-
boratory confirmation of the diagnosis) were used for
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non-specific outcomes are known to be a poor proxy
for influenza, outcomes such as all-cause hospitalization
or ILI usually underestimate VE due to dilution effects
(since many other causes can lead to the same outcome). In
contrast, the outcome ‘influenza/pneumonia hospitalization’
is more specific and might be based on laboratory con-
firmation by some but not all physicians. However, mis-
classification is still possible due to selective testing or
if the discharge diagnosis was only based on clinical
judgment, which can lead to over- or underestimation
of VE. Therefore, laboratory confirmation has been ad-
vocated as a minimum requirement for studies asses-
sing influenza vaccine efficacy or effectiveness [48-51].
However, such data were not available in the studies
analyzed here.
A third limitation concerns the design of available
studies. Namely, no RCTs or other experimental studies
have been performed so far, to determine the effects of
influenza vaccination in the large group of diabetic pa-
tients. In observational studies on the effectiveness of in-
fluenza vaccination in the presence of comorbidities,
two different types of confounding have been described,
which affect the comparability of vaccinated and unvac-
cinated participants. If patients with underlying chronic
diseases are more likely to be vaccinated, selection for
vaccination is confounded by factors that are also related
to clinical outcomes. This scenario is referred to as ‘con-
founding by indication’ [52]. If no adequate statistical
adjustment (e.g., for comorbidities) is made, confound-
ing by indication leads to an underestimation of VE. The
alternative scenario is called ‘healthy vaccinee bias’ and
refers to a situation when patients who are in better
health condition are more likely to be vaccinated [53]. If
not corrected for, healthy vaccinee bias leads to an over-
estimation of VE. We found nearly all of the studies ana-
lyzed here to be at risk of confounding by indication. If
no correct adjustment had been made for comorbidities,
these studies would have underestimated VE. Indication
for healthy vaccinee bias was observed in only one study
in elderly patients. Since identification of both con-
founding by indication and healthy vaccine bias is chal-
lenging, some authors have suggested using off-season
estimates of VE as control period to assess the extent of
residual confounding [54]. Any effect of vaccination
measured during off-seasons is therefore attributable to
confounding. If confounder-adjusted VE estimates do
not differ between influenza season and off-season, re-
sidual confounding is likely to be present. In our meta-
analysis, residual confounding was likely to seriously
affect VE estimates in the elderly but only to a small ex-
tent in working-age adults. This fits well with the possi-
bility of healthy vaccinee bias in the study by Lau et al.
[35], which provided the majority of off-season estimatesfor this analysis. Adjusting for functional status rather
than comorbidities in observational studies might reduce
the impact of residual confounding in observational
studies [55]; however, ultimately, these problems can
only be solved by the conduct of RCTs or by designing
other experimental or quasi-experimental studies which
minimize bias and confounding.
Interpretation of meta-analysis results
Our meta-analysis indicated that in working-age adults
with diabetes, influenza vaccination prevents hospitaliza-
tions but not death or ILI. In contrast to the outcome
‘all-cause hospitalization’, for which a significant off-
season effect suggests residual confounding, the more
specific outcome ‘influenza/pneumonia hospitalization’
seems more robust and not impaired by residual con-
founding. For this outcome, only one observational
study was identified and showed a VE of 43%, thereby
indicating a moderate effectiveness. Why no effect of
vaccination was found against all-cause mortality and
ILI remains unclear; however, this might be due to the
fact that the number of deaths in this age-group is small
and that the effect against ILI is diluted through the un-
specific clinical case-definition of the outcome itself
[56].
Regarding elderly diabetic patients, the results of our
meta-analysis showed protection against all-cause mor-
tality and hospitalizations as well as against ILI. How-
ever, residual confounding was likely in all outcomes as
demonstrated by significant off-season VE estimates ex-
cept for all-cause mortality. For all-cause mortality, the
VE estimate during off-season had a wide 95% CI and
the point estimate was not significantly different from
the VE point estimate during influenza season. In fact,
studies among elderly people have found that VE esti-
mates against all-cause deaths were higher than expected
given the observed effectiveness against laboratory-
confirmed influenza cases [57,58]. It was concluded that
selection bias have led observational studies to greatly
exaggerate influenza vaccine benefits in this particular
age group [55,59]. Overall, these findings indicate a VE
overestimation for all outcomes in elderly diabetic pa-
tients, and no precise estimate of a preventive effect can
be inferred from these data.
Strengths and limitations of this review
Our systematic review has several strengths. It is the first
systematic evaluation of the literature on this topic, cover-
ing published data on more than 170,000 diabetic patients.
We performed an outcome- and age group-specific quality
assessment of individual studies and assessed the quality
of evidence of each reported outcome using the GRADE
methodology. We paid particular attention to residual
confounding in the observational studies by comparing
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tained outside seasons. Furthermore, interpreting and
drawing conclusions from the studies was challenging.
This was mainly due to the identified limitations of the in-
cluded studies, namely the lack of RCTs and other experi-
mental studies and the high risk of bias. In addition, only
one of the included studies provided data on type of dia-
betes or glycemic control. Given the wide spectrum of dis-
ease severity and treatment success in diabetic patients,
influenza VE might differ substantially between patient
sub-groups. Factors such as severity of disease and treat-
ment success, differences in study settings and healthcare
systems, and methodological variations, might have caused
the statistical heterogeneity observed for some outcomes.
However, due to the small number of studies it was not
possible to investigate this issue by subgroup analysis.Conclusions
The WHO and several NITAGs recommend seasonal in-
fluenza vaccination of patients with diabetes, regardless of
age and severity of the diabetic disease [3-7]. For NITAGs,
knowledge about the strength of the vaccine effect and the
quality of the underlying evidence are crucial for decision
making. However, there are also other relevant key criteria
such as disease severity, burden of the disease in a popula-
tion, and the availability of other preventive measures
[60]. Given the large number of people living with diabetes
worldwide, it is surprising that it is impossible to deter-
mine to which extent diabetic patients benefit from sea-
sonal influenza vaccination.
On the other hand, the absence of alternative effective
preventive measures and the good safety profile of sea-
sonal influenza vaccines can still justify the decision to
vaccinate the patient even if the quality of evidence on
the effectiveness is low. This is particularly true if other
underlying risk factors might put the diabetic patient at
an increased risk for severe influenza disease.
Given the low to very low quality of evidence related to
influenza VE in diabetic adults and elderly and the lack of
evidence in children with diabetes, RCTs or carefully con-
ducted quasi-experimental studies using laboratory-
confirmed influenza-specific outcomes (e.g., studies using
instrumental variable method [61]) are urgently needed to
clarify the true effect of influenza vaccination in this im-
portant patient population.Additional files
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